Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space
Pictured: Abstract collage of money, pills, prostate cancer cells and signing a contract/Taylor Tieden for BioSpace When Arvinas agreed to license an oral targeted protein degrader for prostate cancer to Novartis last week, it represented a change in …